An interventional study of No Periadventitial dissection of the SMA and Periadventitial dissection of the SMA in Pancreatic Adenocarcinoma, sponsored by University Hospital Birmingham NHS Foundation Trust. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by University Hospital Birmingham NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Pancreatic Neoplasms with a site in United Kingdom — 42 open to participants now, 58 under way, 11 of them phase 3. Pancreatic Neoplasms · United Kingdom.
Among the 177 studies in Pancreatic Neoplasms with a site in United Kingdom, this one is the 77th largest by planned enrollment of the 134 interventional ones that give a count, is one of 9 that started in 2021, is one of 13 with no phase, reaches primary completion later than 12 of the 57 other live ones, and was the 123rd registered.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,006 are open to participants now.
Browse Pancreatic Neoplasms studies →42 of the 177 studies in Pancreatic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Immuneering Corporation · Sites in United Kingdom, United States, Australia and 6 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in United Kingdom, United States, Austria and 2 more countries
Ages 18+
Incyte Corporation · Sites in United Kingdom, United States, Australia and 19 more countries
Ages 18+
Orion Corporation, Orion Pharma · Sites in United Kingdom, United States, Denmark and 4 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 70 · Phase 3 30
First in 1999; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 120 across the 134 interventional studies, 215 across the 38 observational. Of the 102 that completed or were terminated, 33 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 177 have an industry lead sponsor. The 10 most frequent:
University Hospital Birmingham NHS Foundation Trust is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
University Hospital Birmingham NHS Foundation Trust has 2 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies in Pancreatic Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093231Cambridge University Hospitals NHS Foundation TrustPembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | 2026-11-30 |
| NCT06850623EXACT Therapeutics ASAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | 2026-12-15 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT06447064Imperial College LondonCancer Loyalty Card Study 2 (CLOCS-2) | 2027-02 |
| NCT03536793Hull University Teaching Hospitals NHS TrustTumour Regulatory Molecules in Early Pancreatic Cancer Detection | 2027-02-28 |
Add all 14 to your calendar (.ics) → With an account.
Among the 177 studies in Pancreatic Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. There is lack of standardisation of the proposed technique and no grade 1 evidence to support routine use of this technique.
The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.
Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are conventionally judged unresectable with just 10-20% eligible for upfront surgery and a 5-year survival of 10-30%. Microscopically positive margins (R1) have been associated with poorer survival of patients undergoing pancreaticoduodenectomy. The incidence of R1 varies between 16-79% in the published literature and the median survival for patients undergoing R0 resections is between 19-21 months versus 9-13 months for patients undergoing R1. Therefore, to investigate strategies to decrease the rate of R1 resection is crucial to significantly improve the patient survival1.
The SMA margin is positive in 47-77% of these resections, even when the margin is "clear" on the pre-operative staging CT2,4. Many different techniques are in practice and have been described for this part of the pancreaticoduodenectomy procedure, including the use of diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is staying close to the SMA and removing the so called "mesopancreas"3.Peri-adventitial arterial dissection is a technique that has been a commune practise in several pancreatic centres and has been proposed as an effective surgical technique to achieve R0 margins. On the other hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in the definition of a "positive margin", as well as the lack of accurate description of the surgical technique in the majority of the studies, with only about 25% of the studies reporting the use of the technique4. Moreover, none of the published studies have documented standardisation in the use of the technique with regards to the extent of the periadventitial dissection on the SMA, longitudinally and circumferentially.
In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where there is a close relation of the tumour to the arteries in an effort to achieve an R0 resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for resectable tumours has been performed in a subset of patients based on surgeon's preference. The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of 44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates are comparable to the average described by the unit's results and published literature (20.8% of grade B and above complications as per the Clavien-Dindo classification). More specifically, there have been no incidences of vascular related injury or complication related to the technique; or persistent chyle leak (one episode of chyle leak grade A recorded that was managed conservatively).
The goal of this prospective study is to investigate the role of routine peri-adventitial dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes are: length of stay, complications, overall survival, disease free survival and adjuvant treatment uptake.
This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial dissection) study. A pilot phase will determine feasibility to proceed with the rest of the trial and to determine:
Positive SMA margin status rate
Feasibility criteria to be met in order to proceed with the rest of the trial:
For the full trial a sample size of 51 patients per arm has been based on a margin positivity of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power 80% (type A error 0.05).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.
Procedure: Periadventitial dissection of the SMA
For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
Procedure: No Periadventitial dissection of the SMA
lymphoneural tissue around SMA left intact
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.
SMA margin status
Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)
Time frame: Recorded at histological examination estimated 2 weeks post-operatively
Length of stay
Number of days to discharge (day 0 being the day of the operation)
Time frame: Recorded at patient discharge (monitored by research team) and analysed at an expected time frame of 2 years (study end)
Complications
categorised by clavien-dindo (grade 1 to 5, higher score = worse)
Time frame: 90 days
adjuvant treatment
percentage of patients receiving adjuvant chemotherapy, type and duration.
Time frame: within 1 year of surgery
Overall survival
The length of time (in months) from day of diagnosis to death or last follow up
Time frame: Analysis at 5 years from start of trial
Disease free survival
length of time (in months) from day of resection until diagnosis of recurrence or last follow up
Time frame: Analysis at 5 years from start of trial
Started Apr 2021 (actual). Primary completion is estimated for Oct 2026, 66 months after the start.
Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 66 months is above that.
Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Birmingham NHS Foundation Trust